Jinqi Xue

ORCID: 0000-0003-4045-8676
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • Cancer Cells and Metastasis
  • Advanced Breast Cancer Therapies
  • Cell Adhesion Molecules Research
  • Cancer Immunotherapy and Biomarkers
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer-related molecular mechanisms research
  • Cancer, Hypoxia, and Metabolism
  • Cancer-related Molecular Pathways
  • Hippo pathway signaling and YAP/TAZ
  • Monoclonal and Polyclonal Antibodies Research
  • Reconstructive Surgery and Microvascular Techniques
  • Peptidase Inhibition and Analysis
  • Ubiquitin and proteasome pathways
  • Breast Lesions and Carcinomas
  • Breast Implant and Reconstruction
  • MicroRNA in disease regulation
  • Immunotherapy and Immune Responses
  • Wnt/β-catenin signaling in development and cancer
  • Metabolism, Diabetes, and Cancer
  • Histone Deacetylase Inhibitors Research
  • Radiomics and Machine Learning in Medical Imaging
  • RNA modifications and cancer
  • Circular RNAs in diseases

China Medical University
2014-2025

Southeast Clinical Oncology Research Consortium
2024

Hanalei Watershed Hui
2024

Icahn School of Medicine at Mount Sinai
2019

New York Academy of Sciences
2019

John Wiley & Sons (United States)
2019

Hudson Institute
2019

Fudan University Shanghai Cancer Center
2013

Fondazione IRCCS Istituto Nazionale dei Tumori
2013

It is known that prolonged glucocorticoid (GC) treatment results in osteoporosis. This study aimed to evaluate the protective effects of curcumin on bones rats with dexamethasone (DXM)-induced In present study, were administered DXM for 60 days induce osteoporosis, and they then treated (100 mg/kg/day) a further days. H&E staining was used observe pathological changes femurs. Serum osteocalcin levels collagen-type I fragments (CTX) examined as bone metabolism markers. The revealed attenuated...

10.3892/ijmm.2015.2432 article EN cc-by-nc-nd International Journal of Molecular Medicine 2015-12-11

Abstract Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is characterized by invasive growth, rapid metastasis and chemoresistance. Trastuzumab an effective treatment for HER2+ cancer; however, trastuzumab resistance leads to relapse metastasis. CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6) has been considered as a new immune checkpoint tumor-induced immunosuppression. The role of CMTM6 in remains unknown. Here, we uncover trastuzumab-resistant cancer....

10.1186/s12943-023-01716-y article EN cc-by Molecular Cancer 2023-01-10

Abstract Failure to achieve complete elimination of triple negative breast cancer (TNBC) stem cells after adjuvant therapy is associated with poor outcomes. Aldehyde dehydrogenase 1 (ALDH1) a marker (BCSCs), and its enzymatic activity regulates tumor stemness. Identifying upstream targets control ALDH + may facilitate TNBC suppression. Here, we show that KK-LC-1 determines the stemness via binding FAT1 subsequently promoting ubiquitination degradation. This compromises Hippo pathway leads...

10.1038/s41467-023-38097-1 article EN cc-by Nature Communications 2023-05-05

Summary Curcumin, an active component of the rhizomes Curcumin longa L ., possesses broad anti‐inflammation and anti‐cancer properties. was previously reported to be capable protecting ovariectomized rats against osteoporosis. However, effect curcumin on glucocorticoid‐induced osteoporosis ( GIO ) is not yet clear. The present study investigated effects dexamethasone (Dex)‐induced in vivo Dex‐induced osteoblast apoptosis vitro . rat model induced by subcutaneous injection Dex for 60 days...

10.1111/1440-1681.12513 article EN Clinical and Experimental Pharmacology and Physiology 2015-10-30

OBJECTIVE: We aimed to explore the potential application of circulating microRNA-451 (miR-451) in serum predicting resistance neoadjuvant chemotherapy (NACT) breast cancer (BC). METHODS: Eighty-two BC patients who underwent NACT were rec

10.3233/cbm-160578 article EN Cancer Biomarkers 2016-03-30

Breast cancer is a threat to the health of women, and metastasis breast cells plays an important role in deterioration cancer. MicroRNAs play critical tumorigenesis development MicroRNA-148a (miR-148a) associated with growth tumor cells. In present study, we investigated miR-148a migration as well underlying mechanism. MiR-148a was found inhibit proliferation To further explore mechanism through which its antitumor role, matrix metalloproteinase-13 (MMP-13) identified target by western blot...

10.1007/s13277-015-3926-9 article EN Tumor Biology 2015-08-22

Background: Integrin family are known as key gears in focal adhesion for triple-negative breast cancer (TNBC) metastasis. However, the integrin independent factor TLN1 remains vague TNBC. Methods: Bioinformatics analysis was performed based on TCGA database and Shengjing Hospital cohort. Western blot RT-PCR were used to detect expression of pathway cells. A small-molecule C67399 screened blocking β1 through a novel computational screening approach by targeting protein-protein binding...

10.7554/elife.68481 article EN cc-by eLife 2022-03-14

Current therapies for HER2-positive breast cancer have limited efficacy in patients with triple-positive (TPBC). We conduct a multi-center single-arm phase 2 trial to test the and safety of an oral neoadjuvant therapy pyrotinib, letrozole dalpiciclib (a CDK4/6 inhibitor) treatment-naïve, stage II-III TPBC Karnofsky score ≥70 (NCT04486911). The primary endpoint is proportion pathological complete response (pCR) axilla. secondary endpoints include residual burden (RCB)-0 or RCB-I, objective...

10.1038/s41467-022-34838-w article EN cc-by Nature Communications 2022-11-17

Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates moderate objective (ORR) hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor radiotherapy preclinical studies, this pilot study aimed to explore the efficacy safety stereotactic body radiation (SBRT)...

10.7554/elife.101583 preprint EN 2025-01-21

Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates moderate objective (ORR) hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor radiotherapy preclinical studies, this pilot study aimed to explore the efficacy safety stereotactic body radiation (SBRT)...

10.7554/elife.101583.1 preprint EN 2025-01-21

Abstract Background Both neoadjuvant chemotherapy and endocrine therapy only result in trivial pathological complete response rates moderate objective (ORR) hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative breast cancer, more promising alternatives are urgently needed. With proven synergistic effect of cyclin dependent kinase 4/6 (CDK4/6) inhibitor radiotherapy preclinical studies, this pilot study aimed to explore the efficacy safety stereotactic body...

10.7554/elife.101583.2 preprint EN 2025-05-15

Tumor metastasis remains the main cause of breast cancer-related deaths, especially delayed cancer distant metastasis. The current study assessed frequency CD44 - /CD24 cells in 576 tissue specimens for associations with clinicopathological features and investigated underlying molecular mechanisms. results indicated that higher (≥19.5%) was associated postoperative Furthermore, triple negative (TNBC) spontaneously converted into + stem (CSCs) properties similar to CSCs from primary human...

10.7554/elife.65418 article EN cc-by eLife 2021-07-28

Background: Emerging data have supported the immunostimulatory role of radiotherapy, which could exert a synergistic effect with immune checkpoint inhibitors (ICIs). With proven effective but suboptimal ICI and chemotherapy in triple-negative breast cancer (TNBC), we designed pilot study to explore efficacy safety neoadjuvant stereotactic body radiotherapy (SBRT) plus adebrelimab TNBC patients. Methods: Treatment-naïve patients received two cycles intravenous (20 mg/kg, every 3 weeks), SBRT...

10.7554/elife.91737 article EN cc-by eLife 2023-12-22

The practice of breast cancer diagnosis and treatment in China varies to that western developed countries. With the unavailability radioactive tracer technique for sentinel lymph nodes biopsy (SLNB), using blue dye alone has been only option China. Also, malignant tumor most Chinese centres heavily relies on intraoperative instant frozen histology which is normally followed by mapping, SLNB potential axillary operations one consecutive session. This appears cause a high false negative rate...

10.1186/s12893-015-0067-4 article EN cc-by BMC Surgery 2015-06-29

Abstract Lipase member H (LIPH), a novel of the triglyceride lipase family. The clinical implications its expression in breast cancer are still unclear. Therefore, this study, we investigated associations between LIPH and tumorigenic behaviours 144 triple‐negative (TNBC) patients. ratio mammosphere‐forming ability CD44+/CD24− stem‐like cells were tested. role cell migration invasion was also evaluated. In addition, effect silencing on mitochondrial respiration determined using Seahorse...

10.1111/jcmm.15549 article EN cc-by Journal of Cellular and Molecular Medicine 2020-07-02

Purpose: We aimed to evaluate whether CEMIP plays any role in the survival outcome of breast cancer (BC) patients, as well explore regulatory mechanism BC. Methods: evaluated expression and prognostic effect BC patients using Oncomine, GEPIA, UALCAN, Kaplan-Meier plotter databases. Additionally, we detected mRNA protein levels normal tissues via PCR western blotting analyses. Through immunochemistry analysis, quantified 233 samples from patients. then analyzed link between outcomes based on...

10.7150/ijms.58067 article EN cc-by-nc International Journal of Medical Sciences 2022-01-01
Coming Soon ...